Interestingly, a growing number of clinical cases have reported favorable outcomes from a subtype of supposedly non-responder microsatellite stable (MSS) CRC, characterized by DNA polymerase ε (POLE) proofreading domain mutations with high tumor mutational burden (TMB). Here, POLE is linked to neoplasm.